Which of the following statements about pegfilgrastim is true?
**Core Concept**
Pegfilgrastim is a long-acting granulocyte-colony stimulating factor (G-CSF) analogue used to stimulate the production of white blood cells, specifically neutrophils, in patients undergoing chemotherapy. It works by binding to the G-CSF receptor, triggering a cascade of signaling pathways that promote neutrophil proliferation and differentiation.
**Why the Correct Answer is Right**
Pegfilgrastim's long-acting effects are due to its covalent attachment of a polyethylene glycol (PEG) moiety, which increases its molecular weight and reduces renal clearance, prolonging its half-life. This allows pegfilgrastim to maintain elevated levels in the bloodstream for an extended period, thereby sustaining neutrophil production. The PEGylation process also reduces immunogenicity and proteolytic degradation, further enhancing its efficacy.
**Why Each Wrong Option is Incorrect**
**Option A:** Pegfilgrastim is not a recombinant human erythropoietin (EPO) analogue, which is used to stimulate red blood cell production. While both drugs are used to mitigate chemotherapy-induced cytopenias, they target different lineages and have distinct mechanisms of action.
**Option B:** Pegfilgrastim is not a monoclonal antibody targeting CD20, which is used in the treatment of certain hematological malignancies. Pegfilgrastim's mechanism of action is centered on G-CSF receptor binding, not antibody-mediated B-cell depletion.
**Option C:** Pegfilgrastim is not an iron chelator, which is used to manage iron overload in patients receiving certain medications or undergoing frequent blood transfusions. Pegfilgrastim's primary function is to stimulate neutrophil production, not to bind or remove iron.
**Clinical Pearl / High-Yield Fact**
When administering pegfilgrastim, it's essential to note that it should be given at least 24 hours after the last dose of chemotherapy to minimize the risk of inducing a tumor flare reaction, a rare but potentially severe complication.